Preoperative Anxiety
Conditions
Keywords
virtual reality, preoperative anxiety, modified Yale Preoperative Anxiety Scale
Brief summary
The primary objective of the study is to utilize the modified Yale Preoperative Anxiety scale (mYPAS), a validated preoperative/procedural anxiety score, to measure preoperative anxiety via distraction in pediatric oncology patients undergoing port access. The hypothesis is that using Virtual Reality (VR) will objectively decrease anxiety scores measured by mYPAS by five percent (primary outcome). The secondary outcome will be the parents or the legally authorized representative (LAR) subjective reports of anxiety with the use of VR. The Kind VR device is used in house at Children's Health in the Dallas and Plano campuses. The VR device used in this study qualifies as exempt from FDA IDE regulations. It is a non-significant risk, non-invasive, interactive video device the user wears like goggles. The study carries minimal risks to the subjects and is designed to minimize patient discomfort from placement or motion sickness. Furthermore, the device has disposable covers for protection against infection and can be sanitized between uses, once the disposable covers are removed. Children's Health System of Texas (CHST) and this research group are not partnering entities with the Kind VR, and the Kind VR device is not being studied. The effect of virtual reality (VR) on preprocedural anxiety as measured by questionnaires and the observations of the modified Yale Preoperative Anxiety Scale (mYPAS) is being studied Most patients coming to the Clinic of Cancer and Blood Disorders (CCBD) are under chronic care for their ongoing disease and are likely to be coming to the CCBD at least twice in a 6-month period. The CCBD schedule will be reviewed by the researchers for patients age 5-12, requiring port access at least twice during the next six-month period. Patient families whose child meets the basic screening criteria, and have no exclusion criteria, will be approached privately as possible participants in the study. Up to 100 subjects will be enrolled over a 2-year period. Once the subject/parent or LAR agrees to participate, study staff will randomize the subjects into which standard of care distraction method for anxiety management they will receive first in this study.
Detailed description
1. After the potential participants signed informed consent and were screened for the ability to participate in the study at a treatment appointment. 2. They then came to their cancer center (CCBD) appointment for port access for chemotherapy and were randomized to the Virtual Reality (VR) distraction group first, OR the Non-Virtual Reality (Non-VR) Distraction group first. 3. At this CCBD visit, they then participated in their port needle access as part of standard of care for their cancer treatment using either VR or non-VR distraction for anxiety mitigation, depending on randomization, and were observed during the needle access with the Modified Yale Pre-procedural Anxiety Scale (mYPAS) to assess anxiety during the needle access procedure. The mYPAS is an objective, validated, observational anxiety assessment tool. 4. In addition, parents were asked subjective questions as to how they thought their child tolerated Port needle access with the VR versus Non-VR accordingly. 5. The study personnel then asked when their next potential cancer center appointment for port access to schedule participation in the second arm according to their randomization stratification. In this way, each study participant served as their own control. 6. At the next possible port needle access appointment, they were once again observed using the mYPAS scale for the 2nd port access, with either VR or Non-VR distraction, depending on initial randomization group. 7. Parents were once again asked subjective questions as to how they thought their child tolerated Port needle access with the VR versus Non-VR accordingly. 8. The participants data could Only be included in the study if they participated in both study arms to completion.
Interventions
Virtual reality game played during port needle access.
Sponsors
Study design
Intervention model description
Randomized Crossover design study will be performed. Subjects will be randomized (1 to 1 randomization) at their initial encounter to either VR or Non-VR. During their second visit patients will be given the alternative mode of care (i.e. patients who initially received VR distraction will be given Non-VR distraction, and patients who initially received Non- VR distraction will receive VR distraction)
Eligibility
Inclusion criteria
* Any patient of the Children's Medical Center CCBD * 5-12 years of age * Patient requiring their port accessed twice or more within a 6 months period * Ability to understand and the willingness to sign a written informed consent.
Exclusion criteria
* Subjects younger than 5 and older than 12 * Patients requiring recovery in PICU or sites other than PACU * If parents or subject is not willing to participate * Subjects with severe developmental delays and subjects with developmental challenges preventing them from keeping the VR device on are also excluded * Patients who will not be in CCBD for port access at least twice in 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Preoperative Anxiety Score in Pediatric Oncology Patients | 2 years | Preoperative anxiety score in pediatric oncology patients as measured by modified Yale Preoperative Anxiety Scale (mYPAS), a validated preoperative/procedural anxiety score. Possible scores range from 23 to 100. Higher score values are correlated with increased preoperative anxiety. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | 2 years | Number of parents or legally authorized representative (LAR) who subjectively report decreased anxiety in their kids (participants in this study) with the use of VR (Virtual Reality) would be calculated based on Parents' questionnaires scored and evaluated for subjective improvement in parental assessment of preoperative anxiety. |
Countries
United States
Participant flow
Pre-assignment details
Out of patients who were initially enrolled in this randomized crossover design, those not randomized or didn't participate in randomization are reported in the Non-Randomized Arm in the table below.
Participants by arm
| Arm | Count |
|---|---|
| Non-VR (Virtual Reality), Then VR The patient is not assigned to play the VR game. mYPAS scoring for port access is done. | 26 |
| VR (Virtual Reality), Then Non-VR The patient is assigned to play the VR game for 15 minutes prior to actual port access procedure start. mYPAS scoring while playing VR device for Port access
Virtual reality: Virtual reality game | 26 |
| Non-Randomized Patients This group was consented but not randomized into the study. | 37 |
| Total | 89 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 0 | 0 | 1 |
| Overall Study | Did not participate in randomization | 0 | 0 | 33 |
| Overall Study | Subject did not want to wear the VR Helmet | 0 | 0 | 2 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Non-VR (Virtual Reality), Then VR | Total | Non-Randomized Patients | VR (Virtual Reality), Then Non-VR |
|---|---|---|---|---|
| Age, Categorical <=18 years | 26 Participants | 89 Participants | 37 Participants | 26 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Diagnosed with Developmental Delay No | 24 Participants | 86 Participants | 37 Participants | 25 Participants |
| Diagnosed with Developmental Delay Yes | 2 Participants | 3 Participants | 0 Participants | 1 Participants |
| History of Claustrophobia No | 23 Participants | 85 Participants | 37 Participants | 25 Participants |
| History of Claustrophobia Yes | 3 Participants | 4 Participants | 0 Participants | 1 Participants |
| History of Motion Sickness No | 22 Participants | 83 Participants | 37 Participants | 24 Participants |
| History of Motion Sickness Yes | 4 Participants | 6 Participants | 0 Participants | 2 Participants |
| Likes Playing Video Games No | 0 Participants | 37 Participants | 37 Participants | 0 Participants |
| Likes Playing Video Games Yes | 26 Participants | 52 Participants | 0 Participants | 26 Participants |
| Number of Times of Previous Port Access Procedures 0 Times | 4 Participants | 8 Participants | 0 Participants | 4 Participants |
| Number of Times of Previous Port Access Procedures >10 Times | 15 Participants | 32 Participants | 0 Participants | 17 Participants |
| Number of Times of Previous Port Access Procedures 1-3 Times | 4 Participants | 6 Participants | 0 Participants | 2 Participants |
| Number of Times of Previous Port Access Procedures 4-6 Times | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Number of Times of Previous Port Access Procedures 7-9 Times | 3 Participants | 4 Participants | 0 Participants | 1 Participants |
| Number of Times of Previous Port Access Procedures Unknown or Not Reported | 0 Participants | 38 Participants | 37 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 5 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 15 Participants | 6 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 3 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) White | 20 Participants | 66 Participants | 27 Participants | 19 Participants |
| Sex: Female, Male Female | 8 Participants | 39 Participants | 23 Participants | 8 Participants |
| Sex: Female, Male Male | 18 Participants | 50 Participants | 14 Participants | 18 Participants |
| Taking Medications for Anxiety, Depression, or Agitation No | 20 Participants | 39 Participants | 0 Participants | 19 Participants |
| Taking Medications for Anxiety, Depression, or Agitation Unknown or Not Reported | 1 Participants | 38 Participants | 37 Participants | 0 Participants |
| Taking Medications for Anxiety, Depression, or Agitation Yes | 5 Participants | 12 Participants | 0 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 52 | 0 / 52 | 1 / 37 |
| other Total, other adverse events | 3 / 52 | 2 / 52 | 0 / 37 |
| serious Total, serious adverse events | 0 / 52 | 0 / 52 | 1 / 37 |
Outcome results
Preoperative Anxiety Score in Pediatric Oncology Patients
Preoperative anxiety score in pediatric oncology patients as measured by modified Yale Preoperative Anxiety Scale (mYPAS), a validated preoperative/procedural anxiety score. Possible scores range from 23 to 100. Higher score values are correlated with increased preoperative anxiety.
Time frame: 2 years
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Non-VR (Virtual Reality) | Preoperative Anxiety Score in Pediatric Oncology Patients | Holding Phase | 31.44 score on a scale |
| Non-VR (Virtual Reality) | Preoperative Anxiety Score in Pediatric Oncology Patients | Induction Phase | 45.38 score on a scale |
| Non-VR (Virtual Reality) | Preoperative Anxiety Score in Pediatric Oncology Patients | Change from Holding to Induction | 13.94 score on a scale |
| VR (Virtual Reality) | Preoperative Anxiety Score in Pediatric Oncology Patients | Holding Phase | 28.26 score on a scale |
| VR (Virtual Reality) | Preoperative Anxiety Score in Pediatric Oncology Patients | Induction Phase | 32.81 score on a scale |
| VR (Virtual Reality) | Preoperative Anxiety Score in Pediatric Oncology Patients | Change from Holding to Induction | 4.55 score on a scale |
Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR
Number of parents or legally authorized representative (LAR) who subjectively report decreased anxiety in their kids (participants in this study) with the use of VR (Virtual Reality) would be calculated based on Parents' questionnaires scored and evaluated for subjective improvement in parental assessment of preoperative anxiety.
Time frame: 2 years
Population: 51 parents completed the VR experience survey, while one parent opted out of completing the survey. (Only data from parents who completed the VR experience survey have been analyzed and reported for this outcome)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Non-VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Holding Phase : Parents Reporting VR Improved Anxiety | 36 participants |
| Non-VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Holding Phase : Parents Reporting VR Did Not Change Anxiety | 15 participants |
| Non-VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Holding Phase : Parents Reporting VR Worsened Anxiety | 0 participants |
| Non-VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Induction Phase : Parents Reporting VR Improved Anxiety | 47 participants |
| Non-VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Induction Phase : Parents Reporting VR Did Not Change Anxiety | 4 participants |
| Non-VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Induction Phase : Parents Reporting VR Worsened Anxiety | 0 participants |
| VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Induction Phase : Parents Reporting VR Did Not Change Anxiety | 4 participants |
| VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Holding Phase : Parents Reporting VR Improved Anxiety | 36 participants |
| VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Induction Phase : Parents Reporting VR Improved Anxiety | 47 participants |
| VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Holding Phase : Parents Reporting VR Did Not Change Anxiety | 15 participants |
| VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Induction Phase : Parents Reporting VR Worsened Anxiety | 0 participants |
| VR (Virtual Reality) | Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR | Holding Phase : Parents Reporting VR Worsened Anxiety | 0 participants |